Cell Lines For Angiogenesis Screening
Background:
The National Cancer Institute's Angiogenesis Core Facility is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize multicolored fluorescent cell lines and software
for high-throughput screening of compounds that regulate
angiogenesis and cytotoxicity.
Angiogenesis is fundamentally important in tissue development,
vascular disease, and cancer progression. The availability of
high-throughput, simple assays for the study of multiple-cell
biological processes, such as angiogenesis, is essential for the
development of therapeutics and diagnostics for disorders governed
by these complex processes.
Technology:
NCI researchers have developed a series of immortalized cell lines,
selected to represent the different cell types found in in vivo
angiogenesis, that constitutively express different fluorescent
proteins. Based on these cell lines, the researchers have
developed several in vitro angiogenesis assays and a software
application that can be used to investigate the relationships
between different cells involved in angiogenesis. This
technology can be used to develop new combinatorial approaches to
boost the efficiency of existing therapeutics and to facilitate the
discovery of new potential single or combination drugs.
Value Proposition:
- Potential to develop a high-throughput screening assay for
angiogenesis or anti-angiogenesis drugs, and to screen compounds
for cytotoxicity;
- No added detection reagents to disrupt assay results;
- Ability to increase efficiency of existing therapeutics and to
facilitate the discovery of new drugs;
- Ability to conduct real-time monitoring of cellular interaction
and activity faster and more efficiently.
- Ability to study cell-cell interaction and screen drugs in
complex 2D and 3D in vitro assays.
- Ability to easily track and study multicellular systems in in
vivo models (including response to drug treatment).
Further R&D Needed:
- Development of additional cells lines representing other
anatomical origins;
- Ectopic expression of additional fluorescent proteins and/or
reporter systems.
- Further development to include the cells in a kit form to
facilitate delivery and usability.
R&D Status:
Preclinical proof of concept. A high-throughput screen for
potential angiogenic drugs, a cytotoxicity assay, and a software
application for analysis of tube formation assays in prototype.
IP Status: U.S. Patent Application
No. 12/060,752 filed 01 April 2008
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #669
This opportunity is also listed under the following categories: